-
1
-
-
10344238569
-
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
-
1. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1529-1542
-
-
Fisher, B.1
Dignam, J.2
Bryant, J.3
-
3
-
-
0027980912
-
Stopping when the experimental regimen does not appear to help
-
3. Wieand S, Schroeder G, O'Fallon JR. Stopping when the experimental regimen does not appear to help. Stat Med 1994;13:1453-1458.
-
(1994)
Stat Med
, vol.13
, pp. 1453-1458
-
-
Wieand, S.1
Schroeder, G.2
O'Fallon, J.R.3
-
5
-
-
0029903614
-
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
-
5. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-1549.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1543-1549
-
-
-
6
-
-
8044243594
-
Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer
-
6. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-1839.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1834-1839
-
-
-
7
-
-
0024506261
-
A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors
-
7. Fisher B, Costantino J, Redmond C, et al. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989;320:479-484.
-
(1989)
N Engl J Med
, vol.320
, pp. 479-484
-
-
Fisher, B.1
Costantino, J.2
Redmond, C.3
-
10
-
-
0020263135
-
An aid to data monitoring in long-term clinical trials
-
10. Halperin M, Lan KKG, Ware JH, et al. An aid to data monitoring in long-term clinical trials. Controlled Clin Trials 1982;3:311-323.
-
(1982)
Controlled Clin Trials
, vol.3
, pp. 311-323
-
-
Halperin, M.1
Lan, K.K.G.2
Ware, J.H.3
-
11
-
-
33746412158
-
Upper bounds for type I and type II error rates in conditional power calculations
-
11. Davis BR, Hardy RJ. Upper bounds for type I and type II error rates in conditional power calculations. Commun Stat Theory Meth 1991;19:3571-3584.
-
(1991)
Commun Stat Theory Meth
, vol.19
, pp. 3571-3584
-
-
Davis, B.R.1
Hardy, R.J.2
-
13
-
-
84972500231
-
Statistical approaches to interim monitoring of medical trials: A review and commentary
-
13. Jennison C, Turnbull BW. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci 1990;5:299-317.
-
(1990)
Stat Sci
, vol.5
, pp. 299-317
-
-
Jennison, C.1
Turnbull, B.W.2
-
14
-
-
0031032503
-
0 embedded in sequential tests
-
0 embedded in sequential tests. Stat Med 1997;16:465-477.
-
(1997)
Stat Med
, vol.16
, pp. 465-477
-
-
Betensky, R.A.1
-
15
-
-
0028146249
-
The what, why and how of Bayesian clinical trials monitoring
-
15. Freedman LS, Spiegelhalter DJ, Parmar MKB. The what, why and how of Bayesian clinical trials monitoring. Stat Med 1994;13:1371-1383.
-
(1994)
Stat Med
, vol.13
, pp. 1371-1383
-
-
Freedman, L.S.1
Spiegelhalter, D.J.2
Parmar, M.K.B.3
-
17
-
-
0030463407
-
Five years of tamoxifen - Or more?
-
17. Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst 1996;88:1791-1793.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1791-1793
-
-
Peto, R.1
-
18
-
-
0029904559
-
Tamoxifen: The long and short of it
-
18. Swain SM. Tamoxifen: the long and short of it. J Natl Cancer Inst 1996;88:1510-1512.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1510-1512
-
-
Swain, S.M.1
-
19
-
-
0000388854
-
Asymmetric group sequential boundaries for monitoring clinical trials
-
19. DeMets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 1982;69:661-663.
-
(1982)
Biometrika
, vol.69
, pp. 661-663
-
-
DeMets, D.L.1
Ware, J.H.2
-
20
-
-
0002296743
-
Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis
-
20. Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plan Infer 1994;42:19-35.
-
(1994)
J Stat Plan Infer
, vol.42
, pp. 19-35
-
-
Pampallona, S.1
Tsiatis, A.A.2
-
21
-
-
0020729398
-
Group sequential clinical trials with triangular continuation regions
-
21. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983;39:227-236.
-
(1983)
Biometrics
, vol.39
, pp. 227-236
-
-
Whitehead, J.1
Stratton, I.2
-
23
-
-
0029834102
-
Assessing whether to perform a confirmatory randomized clinical trial
-
23. Parmar MKB, Ungerleider RS, Simon R. Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst 1996;88:1645-1651.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1645-1651
-
-
Parmar, M.K.B.1
Ungerleider, R.S.2
Simon, R.3
-
24
-
-
0030595683
-
When is a confirmatory randomized clinical trial needed?
-
24. Berry DA. When is a confirmatory randomized clinical trial needed? J Natl Cancer Inst 1996;88:1606-1607.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1606-1607
-
-
Berry, D.A.1
-
25
-
-
0030055509
-
Randomized trial of five years of adjuvant tamoxifen with continuous therapy for operable breast cancer
-
The Scottish Cancer Trials Breast Group
-
25. Stewart HJ, Forrest AP, Everington D. Randomized trial of five years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74:797-799.
-
(1996)
Br J Cancer
, vol.74
, pp. 797-799
-
-
Stewart, H.J.1
Forrest, A.P.2
Everington, D.3
-
26
-
-
0030479062
-
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node positive breast cancer
-
26. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node positive breast cancer. J Natl Cancer Inst 1996;88:1828-1833.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1828-1833
-
-
Tormey, D.C.1
Gray, R.2
Falkson, H.C.3
|